Ovarian cancer: Weekly or 3-weekly paclitaxel are equally effective

Nature Reviews Clinical Oncology (req's $$$ to access)

 Patients with ovarian cancer typically receive paclitaxel plus carboplatin, and many are also treated with bevacizumab. Now, data from a randomized phase III trial comparing 3-weekly paclitaxel with a lower, weekly dose reveal no significant differences in progression-free survival (PFS) among newly-diagnosed patients with previously untreated ovarian cancer on either…

 Read the full article

• Subscribe to Nature Reviews Clinical Oncology for full access: $199

  Subscribe Purchase article full text and PDF: $8